Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FDK83
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $148,348
Award facts
- Contract value 100% obligated
- $148,347.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $148,347.90 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. This firm fixed-price delivery order, issued on July 30, 2025, with an ultimate completion date of August 20, 2025, was executed without a set-aside designation. The contract falls under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, which carries a total value of $499,999,999 and remains valid through November 2026. This IDC framework enables DLA to issue delivery orders for a comprehensive range of pharmaceutical products supporting medical supply requirements for military health facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through consistent performance delivering branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites. The company's portfolio includes oncology treatments, specialty medications, vaccines, and auto-injectors, positioning it as a trusted vendor for specialized pharmaceutical products such as Entyvio, a biologic immunosuppressant therapy. This delivery order represents routine procurement activity under the established DLA pharmaceutical supply contract, ensuring continuous availability of essential medications to military medical facilities.
Quick answers
Who was awarded contract SPE2DB25FDK83?
SPE2DB25FDK83 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 30, 2025.
How much is contract SPE2DB25FDK83 worth?
The government has obligated $148,348 on SPE2DB25FDK83.
Is contract SPE2DB25FDK83 an order under another contract?
Yes. SPE2DB25FDK83 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB25FDK83 competed?
The extent of competition for SPE2DB25FDK83 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award